MRK Jun 2024 118.000 put
| Previous close | 0.2300 |
| Open | 0.2300 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 118.00 |
| Expiry date | 2024-06-28 |
| Day's range | 0.2300 - 0.2300 |
| Contract range | N/A |
| Volume | |
| Open interest | 9 |
- Yahoo Finance Video
FDA approves Merck's pneumonia vaccine for adults
The Food and Drug Administration (FDA) has approved Merck's (MRK) new vaccine to protect adults from pneumonia. Yahoo Finance's Anjalee Khemlani reports more on how the vaccine works as the pharmaceutical company awaits the Centers for Disease Control's (CDC) recommendation. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl
BenzingaCovid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a treatment forpatients suffering from specific type of endometrial cancer. Its pharma peer, BioNTech SE (NASDAQ: BNTX) wasn’t as lucky as also on Monday, the FDA put its experimental cancer drug study on partial clinical hold. Combining Immunotherapy And Chemotherapy Is Emerging As A New Standard In Ca
ZacksMerck's (MRK) 21-Valent Pneumococcal Jab Gets FDA Approval
Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive/V116, becomes the first PCV specifically designed for adults to be approved by the FDA.
